These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28610781)

  • 1. Pilot studies of a human BCG challenge model.
    Blazevic A; Xia M; Turan A; Tennant J; Hoft DF
    Tuberculosis (Edinb); 2017 Jul; 105():108-112. PubMed ID: 28610781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.
    Blazevic A; Edwards RL; Xia M; Eickhoff CS; Hamzabegovic F; Meza KA; Ning H; Tennant J; Mosby KJ; Ritchie JC; Girmay T; Lai L; McCullough M; Beck A; Kelley C; Edupuganti S; Kabbani S; Buchanan W; Makhene MK; Voronca D; Cherikh S; Goll JB; Rouphael NG; Mulligan MJ; Hoft DF
    J Infect Dis; 2024 May; 229(5):1498-1508. PubMed ID: 38019956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: Protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations.
    Sharpe S; White A; Sarfas C; Sibley L; Gleeson F; McIntyre A; Basaraba R; Clark S; Hall G; Rayner E; Williams A; Marsh PD; Dennis M
    Tuberculosis (Edinb); 2016 Dec; 101():174-190. PubMed ID: 27865390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination.
    Lin MY; Geluk A; Smith SG; Stewart AL; Friggen AH; Franken KL; Verduyn MJ; van Meijgaarden KE; Voskuil MI; Dockrell HM; Huygen K; Ottenhoff TH; Klein MR
    Infect Immun; 2007 Jul; 75(7):3523-30. PubMed ID: 17502400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination.
    Harris SA; Meyer J; Satti I; Marsay L; Poulton ID; Tanner R; Minassian AM; Fletcher HA; McShane H
    J Infect Dis; 2014 Apr; 209(8):1259-68. PubMed ID: 24273174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity.
    Hoft DF; Worku S; Kampmann B; Whalen CC; Ellner JJ; Hirsch CS; Brown RB; Larkin R; Li Q; Yun H; Silver RF
    J Infect Dis; 2002 Nov; 186(10):1448-57. PubMed ID: 12404160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of individual-level factors on Ex vivo mycobacterial growth inhibition: Associations of immune cell phenotype, cytomegalovirus-specific response and sex with immunity following BCG vaccination in humans.
    Prabowo SA; Smith SG; Seifert K; Fletcher HA
    Tuberculosis (Edinb); 2019 Dec; 119():101876. PubMed ID: 31698310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variable BCG efficacy in rhesus populations: Pulmonary BCG provides protection where standard intra-dermal vaccination fails.
    Verreck FAW; Tchilian EZ; Vervenne RAW; Sombroek CC; Kondova I; Eissen OA; Sommandas V; van der Werff NM; Verschoor E; Braskamp G; Bakker J; Langermans JAM; Heidt PJ; Ottenhoff THM; van Kralingen KW; Thomas AW; Beverley PCL; Kocken CHM
    Tuberculosis (Edinb); 2017 May; 104():46-57. PubMed ID: 28454649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical reactogenicity of intradermal bacille Calmette-Guérin vaccination.
    Hoft DF; Leonardi C; Milligan T; Nahass GT; Kemp B; Cook S; Tennant J; Carey M
    Clin Infect Dis; 1999 Apr; 28(4):785-90. PubMed ID: 10825039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of a Human Bacille Calmette-Guérin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity.
    Minhinnick A; Harris S; Wilkie M; Peter J; Stockdale L; Manjaly-Thomas ZR; Vermaak S; Satti I; Moss P; McShane H
    J Infect Dis; 2016 Mar; 213(5):824-30. PubMed ID: 26450421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic Long Peptide Derived from Mycobacterium tuberculosis Latency Antigen Rv1733c Protects against Tuberculosis.
    Coppola M; van den Eeden SJ; Wilson L; Franken KL; Ottenhoff TH; Geluk A
    Clin Vaccine Immunol; 2015 Sep; 22(9):1060-9. PubMed ID: 26202436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin.
    Minassian AM; Satti I; Poulton ID; Meyer J; Hill AV; McShane H
    J Infect Dis; 2012 Apr; 205(7):1035-42. PubMed ID: 22396610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune gene networks of mycobacterial vaccine-elicited cellular responses and immunity.
    Huang D; Qiu L; Wang R; Lai X; Du G; Seghal P; Shen Y; Shao L; Halliday L; Fortman J; Shen L; Letvin NL; Chen ZW
    J Infect Dis; 2007 Jan; 195(1):55-69. PubMed ID: 17152009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attrition of T-cell functions and simultaneous upregulation of inhibitory markers correspond with the waning of BCG-induced protection against tuberculosis in mice.
    Nandakumar S; Kannanganat S; Posey JE; Amara RR; Sable SB
    PLoS One; 2014; 9(11):e113951. PubMed ID: 25419982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
    Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
    Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of new tuberculosis vaccine in children.
    Pang Y; Zhao A; Cohen C; Kang W; Lu J; Wang G; Zhao Y; Zheng S
    Hum Vaccin Immunother; 2016 Apr; 12(4):960-70. PubMed ID: 27002369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simplified mycobacterial growth inhibition assay (MGIA) using direct infection of mouse splenocytes and the MGIT system.
    Yang AL; Schmidt TE; Stibitz S; Derrick SC; Morris SL; Parra M
    J Microbiol Methods; 2016 Dec; 131():7-9. PubMed ID: 27650198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of Genome Region of Difference 4 (RD4) on Mycobacterial Virulence and BCG Efficacy.
    Ru H; Liu X; Lin C; Yang J; Chen F; Sun R; Zhang L; Liu J
    Front Cell Infect Microbiol; 2017; 7():239. PubMed ID: 28642843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.